Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_assertion type Assertion NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_head.
- NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_assertion description "[GR expression levels were unchanged in non-BRCA1-mutated, non-BRCA2-mutated and BRCA2-mutated ovarian cancer compared to their normal tissues; BRCA1 repression (BRCA1 mutation or BRCA1 promoter hypermethylation) ovarian cancer showed decreased GR levels compared to normal tissue; there was a positive correlation between BRCA1 and GR expression in human ovarian cancer specimens; BRCA1 knockdown was effective at inhibiting GR expression, and overexpression of BRCA1 induces an increase in GR levels in ovarian cancer cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_provenance.
- NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_assertion evidence source_evidence_literature NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_provenance.
- NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_assertion SIO_000772 24629067 NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_provenance.
- NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_assertion wasDerivedFrom befree-2016 NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_provenance.
- NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_assertion wasGeneratedBy ECO_0000203 NP1163891.RAc1669Mf50XKkDE_kyJvCBs5i-ZpPJNQ3T1Wo8yAR4U4130_provenance.